Skip to main content
CellSeed Inc. logo

CellSeed Inc. — Investor Relations & Filings

Ticker · 7776 ISIN · JP3423530009 T Manufacturing
Open in API
Filings indexed 65 across all filing types
Latest filing 2026-03-26 Regulatory Filings
Country JP Japan
Listing T 7776

About CellSeed Inc.

https://www.cellseed.com/en/

CellSeed Inc. is a regenerative medicine company centered on the research, development, and commercialization of its proprietary "cell sheet engineering" technology. This innovative platform enables the creation and harvesting of intact sheets of cultured cells without enzymatic treatment, preserving the extracellular matrix and cell-to-cell junctions critical for therapeutic efficacy. The company's business is structured around three core activities: the development of its own pipeline of cell sheet-based therapies for tissue regeneration, the sale of specialized temperature-responsive cell cultureware and related equipment, and the provision of contract development and manufacturing (CDMO) services for regenerative medicine products.

Recent filings

Filing Released Lang Actions
確認書
Regulatory Filings Classification · 1% confidence The document is titled '確認書' (Confirmation Letter) and explicitly references the Financial Instruments and Exchange Act (金融商品取引法). It serves as an officer certification confirming the accuracy of the company's Annual Securities Report (有価証券報告書). According to the 'CERTIFICATION RULE', documents that are primarily officer certifications or attestations should be classified as Regulatory Filings (RNS), even if they reference a specific report type. FY 25
2026-03-26 Japanese
有価証券報告書－第25期(2025/01/01－2025/12/31)
Annual Report Classification · 1% confidence The document is a Japanese '有価証券報告書' (Yuuka Shouken Houkokusho), which is the standard Japanese equivalent of an Annual Report (10-K). It contains detailed financial statements, business indicators, and management information for the fiscal year ending December 31, 2025. It is not an announcement or a summary, but the full regulatory filing itself. FY 2025
2026-03-26 Japanese
有価証券届出書（参照方式）
Capital/Financing Update Classification · 1% confidence The document is a 'Securities Registration Statement' (有価証券届出書) filed with the Kanto Local Finance Bureau by CellSeed Inc. It details the issuance of new share acquisition rights (stock options/warrants) via a third-party allotment. This type of filing is a formal regulatory document concerning capital structure changes and financing activities, which falls under the 'Capital/Financing Update' category.
2025-11-20 Japanese
確認書
Report Publication Announcement Classification · 1% confidence The document is a 'Confirmation Letter' (Kakunin-sho) filed under Article 24-5-2 of the Financial Instruments and Exchange Act in Japan, which accompanies a semi-annual/quarterly report. While it references the 'Second Quarter Report' (第２四半期報告書), the document itself is the formal confirmation statement required by Japanese regulatory law to accompany the filing. Since it is a specific regulatory filing required by the Financial Services Agency (Kanto Local Finance Bureau) and does not contain the full financial statements themselves, it falls under the RNS (Regulatory Filings) category as a formal regulatory submission.
2025-08-14 Japanese
半期報告書－第25期(2025/01/01－2025/12/31)
Interim / Quarterly Report Classification · 1% confidence The document is a '半期報告書' (Semi-Annual Report) filed by CellSeed Inc. with the Kanto Local Finance Bureau under the Financial Instruments and Exchange Act. It contains detailed financial statements (Balance Sheet, Income Statement) for the interim period ending June 30, 2025. As it is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial data, it is classified as an Interim/Quarterly Report. H1 2025
2025-08-14 Japanese
臨時報告書
AGM Information Classification · 1% confidence The document is titled "臨時報告書" (Extraordinary Report/Timely Disclosure Report) and is filed with the Kanto Local Finance Bureau. The filing reason explicitly states that it is submitted because resolutions were passed at the company's 24th Annual General Meeting (AGM) held on March 25, 2025, pursuant to Article 24-5, Paragraph 4 of the Financial Instruments and Exchange Act. The content details the resolutions passed, including capital reduction, surplus appropriation, and the election of directors. Since the document reports the official results of shareholder votes from a general meeting, the most appropriate classification is Declaration of Voting Results & Voting Rights Announcements (DVA). Although it relates to an AGM, DVA specifically covers the *results* of the vote, which is the core content here.
2025-03-27 Japanese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.